Want to join the conversation?
JP Morgan analyst Tien-tsin Huang questions $FISV on its ability to upgrade its EPS target given that's a higher margin component. CFO Robert Hau says that the termination fees is by far the largest single impacting item or the unplanned item in its estimated results for 2016. The mix of the revenue was working quite favorably for $FISV.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?